Filtros de búsqueda

Lista de obras de

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

artículo científico publicado en 2013

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

artículo científico publicado en 2019

A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer ⬇️

artículo científico publicado el 24 de septiembre de 2011

A Personalized Physical Activity Program With Activity Trackers and a Mobile Phone App for Patients With Metastatic Breast Cancer: Protocol for a Single-Arm Feasibility Trial

article

A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer

artículo científico publicado en 2020

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study.

artículo científico publicado en 2016

A candidate molecular signature associated with tamoxifen failure in primary breast cancer

artículo científico publicado en 2008

A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers

artículo científico publicado en 2014

A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer

artículo científico publicado en 2014

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

artículo científico publicado en 2016

A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer

artículo científico publicado en 2008

A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study

artículo científico publicado en 2007

A response letter to comments on "Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016"

artículo científico publicado en 2020

A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer

scientific article published on 14 September 2013

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

artículo científico publicado en 2016

Abstract 2574: Interleukin-7 (CYT107) treatment in lymphopenic 1stline metastatic breast carcinoma patients treated with chemotherapy regimen (Capecitabine) favors the restoration of T-cell subsets number

Abstract CT333: Elypse-7: A randomized, placebo-controlled, Phase 2a evaluating the impact of IL-7 immunotherapy on CD4 count, risks of severe haematological toxicity and tumor progression in metastatic breast cancer patients

article

Abstract OT1-03-05: TROPION-Breast02: Phase 3, open-label, randomized study of first-line datopotamab deruxtecan versus chemotherapy in patients with locally recurrent inoperable or metastatic TNBC who are not candidates for anti-PD-(L)1 therapy

artículo científico publicado en 2023

Abstract PD15-01: Impact of <i>ESR1</i> mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated, advanced breast ca

artículo científico publicado en 2022

Adjuvant chemotherapy for breast cancer and targeted therapies

artículo científico publicado en 2008

Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015

artículo científico publicado en 2015

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): ...

artículo científico publicado en 2015

Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer

artículo científico publicado en 2016

Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer

artículo científico publicado en 2020

Are antiangiogenic antibodies universal for solid tumor?

artículo científico publicado en 2007

Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study

artículo científico publicado en 2012

Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study

artículo científico publicado en 2019

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

artículo científico publicado en 2017

Author Correction: Genomic characterization of metastatic breast cancers

scientific article published on 01 August 2019

BM-18PROLONGED RESPONSE WITH BEVACIZUMAB + NAVELBINE AS THIRD LINE OF TREATMENT OF BREAST CANCER LEPTOMENINGEAL METASTASES: A CASE REPORT.

artículo científico publicado en 2014

Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series.

artículo científico publicado en 2009

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

artículo científico publicado en 2016

Body weight change in women receiving adjuvant chemotherapy for breast cancer: a French prospective study.

artículo científico publicado en 2009

Brain metastases from HER2-positive breast cancer – Authors' reply ⬇️

artículo científico publicado el 1 de enero de 2013

Breast cancer screening: On our way to the future

artículo científico publicado en 2016

Breast cancer with synchronous metastases: trends in survival during a 14-year period

artículo científico publicado en 2004

Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells.

artículo científico publicado en 2013

Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin- and CD1a(+)CD86(+)Langerin+ phenotypes.

artículo científico publicado en 2004

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

artículo científico publicado en 2017

CD4 lymphopenia to identify end-of-life metastatic cancer patients

artículo científico publicado en 2012

Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial ⬇️

artículo científico publicado el 17 de diciembre de 2012

Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994–1998 and 2003–2006

scientific article published on 24 December 2010

Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer ⬇️

artículo científico publicado en 2015

Clinical practice guidelines: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report)

artículo científico publicado en 2004

Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis

artículo científico publicado en 2013

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).

artículo científico publicado en 2014

Comparison of Artificial Neural Network with Logistic Regression as Classification Models for Variable Selection for Prediction of Breast Cancer Patient Outcomes

scholarly article by Valérie Bourdès et al published 2010 in Advances in Artificial Neural Systems

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort

artículo científico publicado en 2017

Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016

scientific article published on 02 March 2020

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

artículo científico publicado en 2015

Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France

scientific article published on 01 January 2006

Cyclooxygenase 2 and breast cancer. From biological concepts to clinical trials

artículo científico publicado en 2004

Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials

artículo científico publicado en 2004

Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer

artículo científico publicado en 2004

Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics

article

Development of a rule based prognostic tool for HER 2 positive breast cancer patients

artículo científico publicado en 2007

Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells

artículo científico publicado en 2011

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study

artículo científico publicado en 2013

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.

artículo científico publicado en 2016

Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial

artículo científico publicado en 2020

Elaborating patient information with patients themselves: lessons from a cancer treatment focus group

artículo científico publicado en 2003

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

scientific article published on 04 September 2019

Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens

artículo científico publicado en 2003

Erratum to "First-line ribociclib plus letrozole for postmenopausal women with HR+, HER2- ABC: MONALEESA-2 safety results" [Breast 36 (Suppl. 1) (November 2017) S44-S45]

artículo científico publicado en 2018

Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.

artículo científico publicado en 2018

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

artículo científico publicado en 2012

Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer.

artículo científico publicado en 2010

Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study

artículo científico publicado en 2020

Feasibility of an exercise and nutritional intervention for weight management during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial

artículo científico publicado en 2019

Fifteen important questions for oncology to be addressed from 2015

scientific article published on 01 June 2015

Final Results of ERASME-4: A Randomized Trial of First-Line Docetaxel plus either Capecitabine or Epirubicin for Metastatic Breast Cancer ⬇️

artículo científico publicado el 6 de julio de 2011

First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.

artículo científico publicado en 2012

First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.

artículo científico publicado en 2018

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients

artículo científico publicado en 2016

Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer

artículo científico publicado en 2010

Genomic characterization of metastatic breast cancers

artículo científico publicado en 2019

Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis

artículo científico publicado en 2021

Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy

artículo científico publicado en 2013

High incidence of mammary intraepithelial neoplasia development in Men1-disrupted murine mammary glands.

artículo científico publicado en 2013

High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR

artículo científico publicado en 2020

ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells

artículo científico publicado en 2012

IL-6 as an intracrine growth factor for renal carcinoma cell lines

artículo científico publicado en 2004

Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort

artículo científico publicado en 2020

Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort

scientific article published on 13 November 2019

Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), <i>PIK3CA</i>-mutated a

artículo científico publicado en 2021

Impaired IFN- Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression

article

Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations

artículo científico publicado en 2016

Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials

scientific article published on 23 August 2018

Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.

artículo científico publicado en 2015

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

artículo científico publicado en 2020

LKB1 when associated with methylatedERα is a marker of bad prognosis in breast cancer

artículo científico publicado en 2014

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

artículo científico publicado en 2009

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study ⬇️

artículo científico publicado el 2 de noviembre de 2012

Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer

artículo científico publicado en 2005

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

artículo científico publicado en 2020

Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients.

artículo científico publicado en 2017

Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas

artículo científico publicado en 2009

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients.

artículo científico publicado en 2012

Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma

artículo científico publicado en 2005

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.

artículo científico publicado en 2016

Mechanisms of resistance to endocrine therapies for breast cancer

artículo científico publicado en 2012

MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer

artículo científico publicado en 2015

Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibit

artículo científico publicado en 2013

Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study

artículo científico publicado en 2021

Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organization

artículo científico publicado en 2012

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.

artículo científico publicado en 2016

Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes

scientific article published on 22 April 2011

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

artículo científico publicado en 2012

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial

artículo científico

Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer

artículo científico publicado en 2008

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

artículo científico publicado en 2017

New therapeutical strategies in metastatic hormone-dependent breast cancer

artículo científico publicado en 2015

Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).

artículo científico publicado en 2017

Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge.

artículo científico publicado en 2008

PI3K targeting in breast cancer: the end of the beginning?

artículo científico publicado en 2016

Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution

artículo científico publicado en 2010

Palliative care delivery according to age in 12,000 women with metastatic breast cancer: Analysis in the multicentre ESME-MBC cohort 2008-2016

scientific article published on 14 August 2020

Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data

artículo científico publicado en 2014

Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome

scientific article published on 19 December 2012

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial

scientific article published on 11 February 2019

Pharmacokinetic interaction between pazopanib and cisplatin regimen.

artículo científico publicado en 2016

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

scientific article published on 02 August 2010

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer

artículo científico publicado en 2013

Phase Ib Study of Ribociclib Plus Fulvestrant and Ribociclib Plus Fulvestrant Plus PI3K-Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer

scientific article published on 04 September 2020

Physical activity preferences before and after participation in a 6-month physical activity intervention among women with metastatic breast cancer

artículo científico publicado en 2019

Physicians' preferences for prescribing oral and intravenous anticancer drugs: a Discrete Choice Experiment

artículo científico publicado en 2011

Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials

artículo científico publicado en 2020

Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer

artículo científico publicado en 2020

Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.

artículo científico publicado en 2006

Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer

artículo científico publicado en 2011

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study ⬇️

artículo científico publicado el 7 de mayo de 2012

Rapalog-mediated repression of Tribbles pseudokinase 3 regulates pre-mRNA splicing

artículo científico publicado en 2020

Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.

artículo científico publicado en 2009

Reply to J.-H. Choi et al ⬇️

artículo científico publicado el 1 de febrero de 2013

Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation

scientific article published on June 2010

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

artículo científico publicado en 2016

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.

artículo científico publicado en 2017

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival

artículo científico publicado en 2017

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

artículo científico publicado en 2014

Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort

artículo científico publicado en 2017

Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies

artículo científico publicado en 2013

TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.

artículo científico publicado en 2015

Targeted treatments for breast cancer: a step forward.

artículo científico publicado en 2013

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer

artículo científico publicado en 2013

The role of angiogenesis in endocrine liver metastases: an experimental study

artículo científico publicado en 2007

The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.

artículo científico publicado en 2017

The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer ⬇️

artículo científico publicado el 14 de julio de 2013

Therogenetics: transferring GWAS technology to the clinic

artículo científico publicado en 2015

Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.

artículo científico publicado en 2018

Time-to-event analysis with artificial neural networks: an integrated analytical and rule-based study for breast cancer

artículo científico publicado en 2007

Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases

artículo científico publicado en 2016

Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort

artículo científico publicado en 2019

Treatment of hot flashes in women with a previous diagnosis of breast cancer

artículo científico publicado en 2004

Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab

artículo científico publicado en 2009

Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study

artículo científico publicado en 2013

Treatment strategies for breast cancer brain metastases

scientific article published on 30 November 2020

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

artículo científico publicado en 2019

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data

artículo científico publicado en 2018

Tumor resistance to HER2 inhibitors: the drug sedimentation concept

artículo científico publicado en 2012

UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer

artículo científico publicado en 2018

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATA

artículo científico publicado en 2014

Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis

artículo científico publicado en 2008

Validation of prognostic scores for survival in cancer patients beyond first-line therapy

artículo científico publicado en 2011

[Adjuvant therapies: the example of breast cancer]

artículo científico publicado en 2008

[Adjuvant therapy for breast cancer patients: treatment decision tree from a French cancer network]

artículo científico publicado en 2002

[Adjuvant treatments in breast cancer: interest of completion of axillary dissection in case of micrometastases or isolated tumor cells in sentinel lymph node]

artículo científico publicado en 2012

[Anemia and chemotherapy]

artículo científico publicado en 2003

[Angiogenesis and breast cancer]

artículo científico publicado en 2007

[Antihormonal therapy in breast cancer and mTOR inhibitors]

artículo científico publicado en 2011

[COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de Vence, in collaboration with the Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), the Société d'Imagerie de la FEMme (SI

scientific article published on 01 April 2020

[Clinical development of anti-angiogenic agents in 2002]

scientific article published on 01 January 2003

[Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]]

artículo científico publicado en 2016

[Neoadjuvant chemotherapy and ovarian cancer]

artículo científico publicado en 2006

[Prognostic factors for febrile neutropenia].

artículo científico publicado en 2006

mTOR inhibitors in advanced breast cancer: ready for prime time?

artículo científico

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda